PL352030A1 - Treatment to neurotic disorders - Google Patents

Treatment to neurotic disorders

Info

Publication number
PL352030A1
PL352030A1 PL00352030A PL35203000A PL352030A1 PL 352030 A1 PL352030 A1 PL 352030A1 PL 00352030 A PL00352030 A PL 00352030A PL 35203000 A PL35203000 A PL 35203000A PL 352030 A1 PL352030 A1 PL 352030A1
Authority
PL
Poland
Prior art keywords
treatment
neurotic disorders
neurotic
disorders
Prior art date
Application number
PL00352030A
Other languages
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL352030(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PL352030A1 publication Critical patent/PL352030A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL00352030A 1999-07-08 2000-07-07 Treatment to neurotic disorders PL352030A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders

Publications (1)

Publication Number Publication Date
PL352030A1 true PL352030A1 (en) 2003-07-28

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00352030A PL352030A1 (en) 1999-07-08 2000-07-07 Treatment to neurotic disorders

Country Status (38)

Country Link
US (6) US7271194B2 (enExample)
EP (4) EP1440691A3 (enExample)
JP (1) JP4773011B2 (enExample)
KR (1) KR100604176B1 (enExample)
CN (1) CN1198610C (enExample)
AR (1) AR021155A1 (enExample)
AT (1) ATE339955T1 (enExample)
AU (6) AU782514B2 (enExample)
BG (4) BG110467A (enExample)
BR (1) BR0011578A (enExample)
CA (4) CA2687392A1 (enExample)
CL (3) CL2008003941A1 (enExample)
CO (1) CO5190674A1 (enExample)
CY (1) CY1105806T1 (enExample)
CZ (1) CZ200270A3 (enExample)
DE (1) DE60030861T2 (enExample)
DK (1) DK1200081T3 (enExample)
EA (1) EA006555B1 (enExample)
ES (1) ES2272298T3 (enExample)
HK (1) HK1048069B (enExample)
HR (1) HRP20010820A2 (enExample)
HU (1) HUP0201791A3 (enExample)
IL (5) IL146131A0 (enExample)
IS (1) IS6137A (enExample)
ME (2) MEP2508A (enExample)
MX (1) MXPA01011626A (enExample)
MY (1) MY143278A (enExample)
NO (4) NO329021B1 (enExample)
PL (1) PL352030A1 (enExample)
PT (1) PT1200081E (enExample)
SI (1) SI1200081T1 (enExample)
SK (1) SK82002A3 (enExample)
TR (4) TR200402276T2 (enExample)
TW (1) TWI232101B (enExample)
UA (1) UA77645C2 (enExample)
WO (1) WO2001003694A1 (enExample)
YU (1) YU78701A (enExample)
ZA (1) ZA200108856B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
BR0113011A (pt) * 2000-07-21 2003-07-01 Lundbeck & Co As H Novos compostos e sua utilização como inibidores de transporte de glicina; composição farmacêutica e método do tratamento
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途
ES2233842T3 (es) 2001-07-31 2005-06-16 H. Lundbeck A/S Composicion cristalina que contiene escitalopram.
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
MXPA05005772A (es) * 2002-12-23 2005-08-16 Lundbeck & Co As H Bromhidrato de escitalopram y un metodo para su preparacion.
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (enExample) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO1993009769A1 (en) 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
DK0759299T3 (da) 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
UA62984C2 (en) * 1997-11-11 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DK0957099T3 (da) * 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocykliske carboxamider
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
CA2337507A1 (en) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SK285719B6 (sk) * 1998-10-20 2007-07-06 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukty
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
EP1173431B2 (en) * 1999-04-14 2009-08-26 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1276478A2 (en) 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途

Also Published As

Publication number Publication date
IL170193A (en) 2010-04-29
US20070276035A1 (en) 2007-11-29
HRP20010820A2 (en) 2003-08-31
BG110468A (en) 2010-01-29
CA2687392A1 (en) 2001-01-18
US20040029957A1 (en) 2004-02-12
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
AU2005202686A1 (en) 2005-07-14
UA77645C2 (en) 2007-01-15
US20020086899A1 (en) 2002-07-04
CN1198610C (zh) 2005-04-27
HK1048069A1 (en) 2003-03-21
CL2008003939A1 (es) 2009-06-05
HK1048069B (zh) 2005-12-16
AU782514B2 (en) 2005-08-04
NO329021B1 (no) 2010-07-26
TR200402277T2 (tr) 2005-01-24
BG106279A (bg) 2002-08-30
AU2005202686B2 (en) 2009-01-15
IS6137A (is) 2001-10-30
IL146131A (en) 2007-02-11
ME00032B (me) 2010-02-10
AR021155A1 (es) 2002-06-12
BR0011578A (pt) 2002-03-26
IL170192A (en) 2010-04-29
WO2001003694A1 (en) 2001-01-18
DE60030861T2 (de) 2007-05-03
SK82002A3 (en) 2002-07-02
EP1200081A1 (en) 2002-05-02
AU2008264182A1 (en) 2009-01-29
NO20100334L (no) 2002-01-07
ES2272298T3 (es) 2007-05-01
CZ200270A3 (cs) 2002-04-17
EP1440689A2 (en) 2004-07-28
CY1105806T1 (el) 2011-02-02
CA2687394A1 (en) 2001-01-18
JP4773011B2 (ja) 2011-09-14
YU78701A (sh) 2004-03-12
EP1440690A2 (en) 2004-07-28
BG110466A (en) 2010-01-29
PT1200081E (pt) 2007-01-31
MY143278A (en) 2011-04-15
BG110467A (en) 2010-01-29
ATE339955T1 (de) 2006-10-15
ZA200108856B (en) 2002-12-24
CA2373757A1 (en) 2001-01-18
MXPA01011626A (es) 2002-06-04
TR200200014T2 (tr) 2002-05-21
CO5190674A1 (es) 2002-08-29
CN1360501A (zh) 2002-07-24
TR200402275T2 (tr) 2005-03-21
CL2008003938A1 (es) 2009-05-22
US20040029956A1 (en) 2004-02-12
EP1440690A3 (en) 2004-08-18
EP1440689A3 (en) 2004-08-25
TR200402276T2 (tr) 2005-01-24
US20040029958A1 (en) 2004-02-12
EA006555B1 (ru) 2006-02-24
AU2005202685B2 (en) 2009-01-15
US7265151B2 (en) 2007-09-04
TWI232101B (en) 2005-05-11
CA2373757C (en) 2010-01-05
IL146131A0 (en) 2002-07-25
AU2008264188A1 (en) 2009-05-07
HUP0201791A2 (en) 2002-10-28
AU2005202685A1 (en) 2005-07-14
AU5806100A (en) 2001-01-30
US7271194B2 (en) 2007-09-18
NO20100335L (no) 2002-01-07
HUP0201791A3 (en) 2005-02-28
EP1440691A3 (en) 2004-08-25
US20050101665A1 (en) 2005-05-12
US6960613B2 (en) 2005-11-01
DK1200081T3 (da) 2006-12-27
CA2687396A1 (en) 2001-01-18
EP1200081B1 (en) 2006-09-20
MEP2508A (xx) 2010-02-10
NO20100333L (no) 2002-01-07
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (en) 2004-07-28
NO20020062D0 (no) 2002-01-07
KR100604176B1 (ko) 2006-07-25
AU2005202684B2 (en) 2009-01-15
EA200200137A1 (ru) 2002-06-27
CL2008003941A1 (es) 2009-05-22
KR20020015346A (ko) 2002-02-27
DE60030861D1 (de) 2006-11-02
IL170194A (en) 2010-05-31
JP2003504332A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
GB9925439D0 (en) Hair treatment compositions
PL352030A1 (en) Treatment to neurotic disorders
GB9921659D0 (en) Water treatment
AU9527001A (en) Treatment of T cell disorders
GB9918760D0 (en) Topical treatment
GB9925136D0 (en) Novel treatment
PL349347A1 (en) Novel treatment
GB9926968D0 (en) Treatment of neurological disorders
GB0001710D0 (en) Therapeutic treatment
GB2354944B (en) Skin treatment compositions
GB9929694D0 (en) Water treatment
AU2096002A (en) Therapeutic treatment
AU4838301A (en) Treatment of disorders relating to the serotonergic system
MXPA00012560A (es) Uso de interleucocina-11 para tratar desordenes gastrointestinales.
GB9924942D0 (en) Treatment of movement disorders
GB0206401D0 (en) Side effects treatment
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
TW459534U (en) Herbal therapeutic massaging bar
GB9917535D0 (en) Cosmetic treatment
GB0017951D0 (en) Treatment of movement disorders
GB9904918D0 (en) Skin treatment
GB9907649D0 (en) Skin treatment
GB9924980D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 384041

Country of ref document: PL

Kind code of ref document: A1

VDSO Invalidation of derivated patent or utility model

Ref document number: 384042

Country of ref document: PL

Kind code of ref document: A1

VDSO Invalidation of derivated patent or utility model

Ref document number: 384043

Country of ref document: PL

Kind code of ref document: A1

REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)